Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.
Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Flaherty KT, Bernards R, Lito P, Settleman J, McCormick F.
Wang VE, et al. Among authors: wilson c.
Clin Cancer Res. 2019 Dec 1;25(23):7202-7217. doi: 10.1158/1078-0432.CCR-18-2779. Epub 2019 Sep 12.
Clin Cancer Res. 2019.
PMID: 31515463
Free PMC article.